We read with great interest the recent article by Miller and colleagues (April 2010) 1 reporting their experience with 47 patients who were admitted to the ICU with 2009 infl uenza A(H1N1) [A(H1N1)] virus infection in Utah. The authors stated that the severity of illness and mortality (27%) in their cohort who received usual care for ARDS (ie, low tidal volume, low pressure ventilation) was similar to that demonstrated in the Australia and New Zealand series using extracorporeal membrane oxygen (ECMO).
To the Editor:
We read with great interest the recent article by Miller and colleagues (April 2010) 1 reporting their experience with 47 patients who were admitted to the ICU with 2009 infl uenza A(H1N1) [A(H1N1)] virus infection in Utah. The authors stated that the severity of illness and mortality (27%) in their cohort who received usual care for ARDS (ie, low tidal volume, low pressure ventilation) was similar to that demonstrated in the Australia and New Zealand series using extracorporeal membrane oxygen (ECMO). 1 We would like to point out that the patient characteristics in these two cohorts are not similar, and direct comparison between the two groups is not possible. We would suggest that in the management of patients with A(H1N1)-associated respiratory failure unresponsive to conventional ventilation, ECMO should be considered.
The Australia and New Zealand Extracorporeal Membrane Oxygenation Infl uenza Investigators recently published an exhaustive review of all Australian or New Zealand patients who were treated with ECMO for severe A(H1N1)-associated ARDS in multiple centers. 2 Of the 194 patients given mechanical ventilation for confi rmed A(H1N1) infection, 61 (31%) received ECMO. The overall mortality was 13% (26ր194). The mortality for patients who received mechanical ventilation was 9% (12ր133) and 23% (14ր61) for ECMO. Affected patients were often young adults, were pregnant or postpartum, were obese, had severe respiratory failure before ECMO, and received prolonged mechanical ventilation and ECMO support. 2 A mortality rate of 13% overall and 23% in the ECMO group should be interpreted as a positive outcome, considering the severity of the illness.
The recently published A(H1N1)-specifi c supplements in the Extracorporeal Life Support Organization guidelines expressed the need for a lower threshold for conventional optimal treatment to be considered inadequate and for ECMO to be used promptly. 3 The provision of an ECMO service requires high levels of expertise and extensive staffi ng resources. The expense of ECMO treatment may be further minimized with strategies such as setting up large-scale specialized treatment centers in strategic locations. This would ensure intensive accumulation of management experience as well as facilitate communication and organization within centers, accelerating the advancement of management techniques. As such, ECMO treatment would then be optimized, eventually reducing the duration of ventilatory support required for recovery, making it more cost-effective if increased patient survival is attained. The integration of ECMO into current treatment strategies for A(H1N1)-induced respiratory failure will likely improve patients' outcomes.
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